Vorolanib is a drug with antiangiogenic and antineoplastic activities. In 2023, vorolanib was approved for use in China. It is used in combination with everolimus for the treatment of advanced renal cell carcinoma in patients who have previously received tyrosine kinase inhibitor treatment but failed.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.